S100A3: Potential Drug Target Or Biomarker (G6274)

Target Name: S100A3

NCBI ID: G6274

S100A3

S100A3: Potential Drug Target Or Biomarker

S100A3, also known as protein S100-A3, is a protein that is expressed in various tissues throughout the body. It is a member of the S100 family of proteins, which are known for their role in cell signaling and stress responses. S100A3 has been shown to play a role in a variety of biological processes, including cell signaling, inflammation, and the regulation of ion channels. As a result, S100A3 has potential as a drug target or biomarker.

S100A3 is a 21-kDa protein that is expressed in various tissues, including the brain, heart, liver, and kidneys. It is a member of the S100 family of proteins, which are characterized by the presence of a basic amino acid residue at their C-terminus. This basic residue is important for the protein's stability and can modulate its function in a variety of ways.

One of the key functions of S100A3 is its role in cell signaling. S100A3 has been shown to play a role in a variety of signaling pathways, including the regulation of cell proliferation and the regulation of ion channels. For example, studies have shown that S100A3 can interact with the protein FERMT1 and regulate the formation of new blood vessels. Additionally, S100A3 has been shown to play a role in the regulation of ion channels, including the regulation of neurotransmitter release and the regulation of muscle contractions.

In addition to its role in cell signaling, S100A3 is also involved in the regulation of inflammation. Studies have shown that S100A3 can interact with the protein NF-kappa-B and regulate the expression of genes involved in inflammation. This suggests that S100A3 may play a role in the regulation of inflammatory responses and may be a potential therapeutic target for the treatment of inflammatory disorders.

S100A3 has also been shown to play a role in the regulation of cell adhesion. Studies have shown that S100A3 can interact with the protein cadherin and regulate the formation of tight junctions, which are important for the regulation of cell-cell adhesion. This suggests that S100A3 may play a role in the regulation of cell adhesion and may be a potential therapeutic target for the treatment of diseases that are characterized by disrupted cell-cell adhesion, such as cancer.

Another potential function of S100A3 is its role in the regulation of neurotransmission. Studies have shown that S100A3 can interact with the protein neurotrophin and regulate the release of neurotransmitters, including dopamine and serotonin. This suggests that S100A3 may play a role in the regulation of neurotransmission and may be a potential therapeutic target for the treatment of neurotransmission disorders.

In conclusion, S100A3 is a protein that has been shown to play a variety of roles in various biological processes. Its basic amino acid residue, as well as its ability to interact with other proteins, suggest that it has potential as a drug target or biomarker. Further research is needed to fully understand the functions of S100A3 and its potential as a therapeutic target.

Protein Name: S100 Calcium Binding Protein A3

Functions: Binds both calcium and zinc. May be involved in calcium-dependent cuticle cell differentiation, hair shaft and hair cuticular barrier formation

The "S100A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about S100A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets